Ardea Biosciences, Inc.
Records under this name other than the patents Ardea Biosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 16 patents it holds.
Back to Ardea Biosciences, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,047,050 | 3,4-DI-SUBSTITUTED Pyridine Compound, Methods of Using and Compositions Comprising the Same Lapsed on the fee record Ended Aug 14, 2026 · High confidence | Lapsed on the fee record | Ended Aug 14, 2026 | High confidence |
| US 7,435,752 | N[S(4-ARYL-TRIAZOL-3-YL)ALPHA-MERCAPTOACETYL]-P-AMINO Benzoic Acids as HIV Reverse Transcriptase Inhibitors Term ended Ended no later than Apr 1, 2026 · Medium confidence | Term ended | Ended no later than Apr 1, 2026 | Medium confidence |
| US 7,947,721 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of HIV Reverse Transcriptase Term ended Term ended Aug 25, 2025 · Medium confidence | Term ended | Term ended Aug 25, 2025 | Medium confidence |
| US 8,003,681 | 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-YL)-4H-1,2,4-Triazol-3-Ylthio)ACETIC Acid and Methyl Ester Term ended Term ended Aug 25, 2025 · High confidence | Term ended | Term ended Aug 25, 2025 | High confidence |
| US 8,252,828 | S-Triazolyl Alpha-Mercapto Acetanilides as Inhibitors of HIV Reverse Transcriptase Term ended Term ended Aug 25, 2025 · Medium confidence | Term ended | Term ended Aug 25, 2025 | Medium confidence |
| US 8,481,581 | S-Triazolyl Alpha-Mercapto Acetanilides as Inhibitors of HIV Reverse Transcriptase Term ended Term ended Aug 25, 2025 · High confidence | Term ended | Term ended Aug 25, 2025 | High confidence |
| US 8,946,273 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of HIV Reverse Transcriptase Term ended Term ended Aug 25, 2025 · Medium confidence | Term ended | Term ended Aug 25, 2025 | Medium confidence |
| US 8,354,532 | Pyrrolo [2,3-d] Pyrimidines as Non-Nucleoside Reverse Transcriptase Inhibitors for Treatment of HIV Lapsed on the fee record Ended Jan 15, 2025 · High confidence | Lapsed on the fee record | Ended Jan 15, 2025 | High confidence |
| US 10,772,886 | CXCR-2 Inhibitors for Treating Crystal Arthropathy Disorders Lapsed on the fee record Ended Sep 15, 2024 · High confidence | Lapsed on the fee record | Ended Sep 15, 2024 | High confidence |
| US 8,227,601 | Diaryl-Purines, Azapurines and -Deazapurines as Non-Nucleoside Reverse Transcriptase Inhibitor for Treatment of HIV Lapsed on the fee record Ended Jul 24, 2024 · High confidence | Lapsed on the fee record | Ended Jul 24, 2024 | High confidence |